A Meta-analysis on the Effect of Ulinastatin on Serum Levels of C-Reactive Protein, Interleukin 6, and Tumor Necrosis Factor Alpha in Asian Patients with Acute Pancreatitis

Genet Test Mol Biomarkers. 2016 Mar;20(3):118-24. doi: 10.1089/gtmb.2015.0192. Epub 2016 Jan 18.

Abstract

Objectives: We aimed to investigate the influence of ulinastatin (UTI) on the serum levels of C-reactive protein (CRP), interleukin 6 (IL-6), and tumor necrosis factor alpha (TNF-α) in Asian patients with acute pancreatitis (AP) by performance of a meta-analysis.

Methods: Two investigators independently searched 11 databases, including PUBMED, EBSCO, Ovid, SpringerLink, Wiley, Web of Science, Cochrane Library, Wanfang database, China National Knowledge Infrastructure (CNKI), Chinese Journal Full-text Database, and China Biomedicine Database. The full-text articles were screened and the data were extracted using a standardized data extraction form. All statistical analyses were conducted with Stata software, version 12.0 (Stata Corporation, College Station, TX).

Results: A total of 94 studies were initially retrieved, and 10 studies containing 424 Asian patients with AP were ultimately enrolled in this meta-analysis. The results revealed that the serum levels of CRP, IL-6, and TNF-α in Asian AP patients significantly decreased after UTI therapy (CRP: standardized mean difference [SMD] = 3.26, 95% confidence interval [CI] = 1.69-4.83, p < 0.001; IL-6: SMD = 5.92, 95% CI = 2.09-9.75, p = 0.002; TNF-α: SMD = 4.07, 95% CI = 0.79-7.35, p = 0.015).

Conclusion: The results of this meta-analysis suggest that UTI can effectively depress the serum levels of CRP, IL-6, and TNF-α in Asian patients with AP, and thereby inhibit inflammation.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Asian People
  • C-Reactive Protein / metabolism*
  • China
  • Glycoproteins / therapeutic use*
  • Humans
  • Interleukin-6 / blood*
  • Pancreatitis / blood*
  • Pancreatitis / drug therapy*
  • Trypsin Inhibitors / therapeutic use
  • Tumor Necrosis Factor-alpha / blood*

Substances

  • Glycoproteins
  • Interleukin-6
  • Trypsin Inhibitors
  • Tumor Necrosis Factor-alpha
  • C-Reactive Protein
  • urinastatin